Literature DB >> 9343126

Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections.

B Schurch1, J Hodler, B Rodic.   

Abstract

OBJECTIVES: To correlate clinical and urodynamic findings with MRI in patients with spinal cord injury and detrusor-sphincter dyssynergia who were consecutively treated with transperineal injections of botulinum-A toxin (BTX-A) under EMG control.
METHODS: Six patients with spinal cord injury and upper motor neuron bladder dysfunction associated with detrusor-sphincter dyssynergia were prospectively analysed. One hundred international units (IU) BTX-A (Botox in 1 ml normal saline without preservative) diluted 1 to 1 with 1 ml gadopentetate were injected transperineally under EMG control. MRI was started immediately after needle withdrawal.
RESULTS: In all six patients gadopentetate was located in the external urethral sphincter on MRI. In no patient did traces of gadopentetate appear in the perineal musculature located in the vicinity of the external urethral sphincter. No patient developed resistance to BTX-A. All patients showed an (ongoing) improvement of their voiding function after BTX-A injections.
CONCLUSIONS: Transperineal injections of BTX-A under EMG control are efficient in the release or amelioration of lower urinary tract obstruction due to detrusor sphincter dyssynergia in patients with spinal cord injury. Despite well described methods, EMG of the external urethral sphincter is difficult and it is not possible to definitively exclude false recordings of the surrounding perineal musculature. By the use of MRI it was shown that both the EMG recordings and transperineal injection method are precise.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343126      PMCID: PMC2169779          DOI: 10.1136/jnnp.63.4.474

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  3 in total

1.  Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients.

Authors:  B Schurch; D Hauri; B Rodic; A Curt; M Meyer; A B Rossier
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

2.  Sphincterotomy failure in neurogenic bladder disease.

Authors:  J L Lockhart; B Vorstman; D Weinstein; V A Politano
Journal:  J Urol       Date:  1986-01       Impact factor: 7.450

3.  Is sphincterotomy the best management of the spinal cord injured bladder?

Authors:  J M Vapnek; D R Couillard; A R Stone
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

  3 in total
  9 in total

Review 1.  [Botulinum toxin in urology. Indications and results].

Authors:  B Schurch; A Reitz
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

2.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

Review 3.  Management of bladder, prostatic and pelvic floor disorders.

Authors:  G Brisinda; G Maria; A R Bentivoglio; F Cadeddu; G Marniga; F Brandara; A Albanese
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

4.  Predictors of outcome for urethral injection of botulinum toxin to treat detrusor sphincter dyssynergia in men with spinal cord injury.

Authors:  J M Soler; J G Previnaire; N Hadiji
Journal:  Spinal Cord       Date:  2015-12-29       Impact factor: 2.772

Review 5.  [Botulinum toxin in urology. An inventory].

Authors:  H Schulte-Baukloh; H H Knispel
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

Review 6.  The use of botulinum neurotoxin type A (BoNTA) in urology.

Authors:  A Apostolidis; C J Fowler
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

Review 7.  Use of botulinum toxin for voiding dysfunction.

Authors:  David Eldred-Evans; Prokar Dasgupta
Journal:  Transl Androl Urol       Date:  2017-04

8.  An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction--Preliminary Findings.

Authors:  Paweł Kroll; Ewa Gajewska; Jacek Zachwieja; Magdalena Sobieska; Przemysław Mańkowski
Journal:  Int J Environ Res Public Health       Date:  2016-03-15       Impact factor: 3.390

Review 9.  Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action.

Authors:  Jia-Fong Jhang; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2016-04-21       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.